Sequence information
DRAVP ID DRAVPc071
Name Etesevimab
Sequence Not available
Molecular Formula
Condition/Disease COVID-19
Group Investigational
Type antibody
Description Etesevimab is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.
Active sequence/Structure
Comment
No comments found.
External Links
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT05205759 | Non-inferiority Trial on Monoclonal Antibodies in COVID-19 (MANTICO) | COVID-19 | Terminated | Phase 3 | Azienda Ospedaliera Universitaria Integrata Verona |
| NCT05268601 | COVID-19 and Disease Progression to the Severe Form: A Study on the Use of Monoclonal Antibodies Against SARS-CoV-2 (CONDIVIDIAMO) | COVID-19 | Unknown status | University of Milano Bicocca |
